Table 4. Teriflunomide discontinuations and treatment switches during the study period (2013–2019).
| Patients | |
|---|---|
| (n = 3239) | |
| Was teriflunomide treatment discontinued before the end of follow-up? n (%) | |
| No | 1701 (52.5) |
| Yes | 1538 (47.5) |
| Because of side effects | 645 (41.9) |
| Because of disease breakthrough | 658 (42.7) |
| Because of death | 7 (0.4) |
| Because of pregnancy | 49 (3.2) |
| Because of other/unknown reasons | 181 (11.8) |
| Which drugs did discontinuing patients switch to? | |
| Did not switch to any DMT, n (%) | 234 (15.2) |
| Switched to another DMT, n (%) | 1304 (84.8) |
| Switched to moderate efficacy DMT, n (%) | 604 (46.3) |
| Dimethyl fumarate | 401 (30.8) |
| Glatiramer acetate | 68 (5.2) |
| Teriflunomide* | 52 (4.0) |
| Peginterferon beta-1 | 43 (3.3) |
| Interferon beta-1a im. | 30 (2.3) |
| Interferon beta-1a sc. | 10 (0.8) |
| Switched to high efficacy DMT, n (%) | 692 (53.0) |
| Fingolimod | 316 (24.2) |
| Natalizumab | 230 (17.6) |
| Ocrelizumab | 95 (7.3) |
| Cladribine | 21 (1.6) |
| Alemtuzumab | 14 (1.1) |
| Rituximab | 9 (0.7) |
| Daclizumab | 5 (0.4) |
| Ofatumumab | 2 (0.2) |
| Other | 8 (0.6) |
DMT: Disease-modifying treatment, im: Intramuscular, sc: Subcutaneous.
*these patients re-started teriflunomide treatment after initial discontinuation for various reasons.